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Abstract: There has been a rapid increase in the use of polypharmacy in psychiatry possibly 
due to the introduction of newer drugs, greater availability of these newer drugs, excessive con-
fidence in clinical trial results, widespread prescribing of psychotropic medications by primary 
care, and pressure to augment with additional medications for unresolved side effects or greater 
efficacy. Even the new generation of medications may not hold significant advantages over older 
drugs. In fact, there may be additional safety risks with polypharmacy being so widespread. 
Washout, as a clinical tool, is rarely done in medication management today. Studies have shown 
that augmenting therapy with additional medications resulted in 9.1%–34.1% dropouts due to 
intolerance of the augmentation, whereas studies of medication washout demonstrated only 
5.9%–7.8% intolerance to the washout procedure. These perils justify reconsideration of medi-
cation washout before deciding on augmentation. There are unwarranted fears and resistance 
in the medical community toward medication washout, especially at the moment a physician is 
trying to decide whether to washout or add more medications to the treatment regimen. However, 
medication washout provides unique benefits to the physician: it establishes a new baseline of 
the disorder, helps identify medication efficacy from their adverse effects, and provides clarity 
of diagnosis and potential reduction of drug treatments, drug interactions, and costs. It may 
also reduce overall adverse events, not to mention a potential to reduce liability. After washout, 
physicians may be able to select the appropriate polypharmacy more effectively and safely, if 
necessary. Washout, while not for every patient, may be an effective tool for physicians who 
need to decide on whether to add potentially risky polypharmacy for a given patient. The risks 
of washout may, in some cases, be lower and the benefits may be clearly helpful for diagnosis, 
understanding medication effects, the doctor/patient relationship, and safer use of polypharmacy 
if indicated.
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Introduction
“Polypharmacy” refers to the concurrent use of multiple medications in a single patient. 
However, the use of the term polypharmacy in the published literature is somewhat impre-
cise and has different meanings according to different authors. Most often, the definition 
of polypharmacy is made with regard to the specific number of medications prescribed. 
Thus, polypharmacy is alternatively defined as the use of two or more psychiatric medi-
cations in the same patient,1 or as the use of two or more medications to treat the same 
condition, use of two or more drugs of the same chemical class, or use of two or more 
drugs with the same or similar pharmacologic actions,2 or as prescribing of three or more 
medications for the same indication, or prescribing of two or more medications with the 
same or similar mechanisms of action(s) used for the same indication.3Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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However, using an absolute numeric threshold to define 
polypharmacy is inherently imprecise, because the number 
of medications considered optimal does vary for different 
psychiatric disorders. For example, optimal treatment in 
schizophrenia or in major depressive disorder is thought 
to involve most often one and generally no more than two 
medications – a practice reflected in the design of the large 
National Institutes of Health studies, ie, Clinical Antipsy-
chotic Trials in Intervention Effectiveness (CATIE) and 
Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D).4,5 In contrast, nearly half (48%) of the patients 
with bipolar disorder treated in the best practice pathway 
of the National Institute of Mental Health Systematic 
Treatment Enhancement Program for Bipolar Disorder 
(STEP-BD) study received treatment with three or more 
medications.6
Another factor adding to the imprecision of the defini-
tion is that while use of multiple medications can have 
negative consequences, it can sometimes be an effective 
clinical intervention. Therefore, any meaningful discussion 
of polypharmacy must make the distinction between rational 
and irrational polypharmacy (which are also discussed later in 
this paper); the former representing an attempt to match very 
unusual and severe clinical presentations with pharmacologi-
cal combinations having proven synergistic effect, while the 
latter describe haphazard combinations of medications with 
no distinguishable clinical or pharmacological rationale. 
With these caveats in mind, we will discuss polypharmacy 
as the practice of prescribing more than two medications in 
a single patient for a single indication, or prescribing of two 
or more medications with the same or similar mechanisms of 
action. We will particularly focus on the irrational aspects of 
polypharmacy and their negative consequences for patients. 
We have identified pertinent literature for this review with 
a computer-aided search of the US National Library of 
Medicine PubMed database for articles published between 
1980 and 2011 in English. The key words used for the search 
were “polypharmacy”, “antidepressant augmentation”, 
“antipsychotic polypharmacy”, “polypharmacy in psychia-
try and risk”, “trial and error medications” and “medication 
washout”. The reference lists of reports identified were used 
to find additional publications.
There has been a rapid increase in the use of polypharmacy 
in psychiatry. The reasons may be multifactorial, such as an 
increasing number of available medications targeting new 
and different symptoms and receptors, or even the pressure 
on psychiatrists to focus on medication treatment. Regardless 
of the reasons, the trend is clear, with   psychiatrists now 
frequently seeing patients presenting on multiple   psychiatric 
medications.
Recent research raises doubts about the degree to which 
psychopharmacological treatment has kept pace with our 
advances in understanding the brain and psychiatric   disorders. 
There is a plethora of new psychiatric medications, but there 
is growing recognition that these new generation medications 
may not hold significant advantages over older medications 
despite their higher costs. In 2006, DePaulo7 observed that, 
when viewed together, the three major studies (ie, STAR*D, 
CATIE, and STEP-BD) question whether or not modern 
pharmacological treatments are better than older interventions, 
notwithstanding additional costs. While none of these studies 
(STAR*D, CATIE, and STEP-BD) have focused primarily on 
comparing older and newer treatments, such contrasts8–11 do not 
suggest any dramatic advantages for the newer medications.
In 2009, Insel12 made similar observations to those of 
DePaulo, noting that second-generation medications have 
consistently demonstrated no significant advantage compared 
with first-generation medications in multiple comparative 
effectiveness studies funded by the National Institute of   Mental 
Health. He also felt that current medication regimes help too 
few people improve from the perspective of side effects, and 
a recent prospective study has now even called into question 
the widely held belief that second-generation antipsychotics 
produce a lower incidence of tardive dyskinesia.13
While newer psychotropic medications might have some 
advantages over older ones, we may be using them incorrectly. 
Clearly, there are inadequacies in our current diagnostic 
nomenclature based as it is on descriptive psychiatry. More 
than likely, our diagnoses encompass several biological 
syndromes, which may require different pharmacological 
treatment. The current state of basing therapies on these 
descriptive diagnostic categories is insufficient. In 2011, 
Frances14 suggested that this approach may be limiting. In the 
same article, Insel14 also mentioned that the National Insti-
tute of Mental Health is reallocating resources to reclassify 
psychiatric diagnoses by 2020, and later said they would be 
reformulated under the umbrella of Brain Disorders. Given 
the significant changes taking place, a major concern for 
many psychiatrists is how to select the most effective treat-
ment today, and over the next decade, while we transition 
into an evidence-based neuroscience.14
This paper centers on the risks and benefits of increas-
ingly prevalent polypharmacy and examines the risks and 
benefits of the underutilized tool of medication washout for 
appropriately selected patients. The question arises as to 
whether the risk of adding another medication is less than the Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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risk of washout, a procedure which may also have the advan-
tages of providing valuable information about which current 
medications are actually beneficial and about the patient’s true 
baseline condition. In addition, modern psychiatry may rely 
too highly on medication as the dominant answer. We may 
need to be more humble about our medication use and not 
discount the risks to which we expose our patients. While 
washout is accomplished differently by different providers, 
for the purposes of this paper, the authors taper medication 
allowing 5–7 half-lives as the rule of thumb for clearance. 
The rate of taper depends on the medication, the dose, and 
the amount of time the patient has been on the medicine. 
Guidance for tapering is presented in Figure 1.
Perhaps the most immediate crisis facing the field of psy-
chiatry today is how to best care for the increasing numbers of 
patients who present with significant treatment resistance and 
symptomatology having failed one or more medication trials, 
often involving polypharmacy. A contributing factor may be 
that many patients are getting psychotropic medications from 
physicians not specializing in psychiatry and who are in need 
of better education regarding some of the complex patients 
they often end up treating. The National Comorbidity Survey 
found that by 2003, one in ten adults had been treated with 
an antidepressant in the previous year, 73.6% of which were 
prescribed by a nonpsychiatric physician.15
Among other insights, a comparative analysis of spe-
cific antidepressant strategies in the STAR*D study showed 
modest efficacy rates for the medications used.16 This sug-
gests that clinician persistence and encouraging treatment 
adherence may be more important than the specific choice 
of antidepressants. In their interpretation of the results of 
STAR*D, Gaynes et al16 felt that many primary care providers 
can treat depression in the real world and that a rational plan 
was more important than which drug was used. They defined 
this to include dosing, symptom and side effect monitoring, 
and assuring an adequate trial period. Other independent 
analyses of STAR*D have highlighted the disappointing out-
comes from the study, particularly its low level of sustained 
improvement during follow-up.17–20 Unfortunately, the overly 
favorable interpretations of the results of STAR*D16 have 
fostered further trial and error polypharmacy, frequently with 
no solid clinical or scientific rationale. For treatment-resistant 
depressed patients, this presents its own set of problems.
Polypharmacy – rational  
or trial and error?
Polypharmacy of difficult psychiatric patients is rapidly becom-
ing the norm. In a study of the frequency of   polypharmacy with 
three or more medications at hospital discharge for bipolar 
disorders or unipolar depression, polypharmacy increased from 
3.3% of patients (1974–1979), to 9.3% (1980–1984), to 34% 
(1985–1989), and to 43.8% (1990–1995).21 In another study 
undertaken between 1996 and 2005, psychiatrists significantly 
increased their use of polypharmacy such that outpatient 
visits resulting in two or more prescribed psychotropic drugs 
increased from 42.6% in 1996 to 59.8% in 2005 and psychiatric 
visits resulting in three or more such drugs being prescribed 
doubled, increasing from 16.9% to 33.2%.22 Unfortunately, this 
is a double-edged sword with risks to the patient. Apart from 
the increased danger of adverse events and excess side effects, 
not to mention increased cost of care, the authors noted that 
psychiatrists often got stuck when trying to switch patients to 
another drug; in other words, they became fearful of removing 
the existing medication by erroneously thinking that even if it 
is clearly not working, it may be better than nothing at all, and 
adding another agent might help. This causes the patient to be 
put on an additional medication instead of merely changing 
medications.22 In a recent article on borderline personality 
disorder, Gunderson discussed some concerns about polyphar-
macy, stating that without a clear benefit, medications should 
be stopped before adding a new drug.23
The practice of increased polypharmacy is at least par-
tially driven by the momentum of recent trends that are push-
ing for remission, instead of merely response, as the desired 
outcome, yet current studies24 suggest that drug augmentation 
does not increase the likelihood of achieving this objective. 
Whether or not it is realistic to assume that medication is 
the only answer to psychiatric problems is a topic in itself. 
However, it is unclear how much one can trust the data on 
remission through polypharmacy, considering that selective 
publication and outcome reporting biases inflate benefits from 
drug augmentation in these studies.25
An important recent addition to the debate on the useful-
ness of polypharmacy is the recently reported Combining 
Medication to Enhance Depression Outcomes (CO-MED) 
study.24 In response to the STAR*D reports showing limited 
efficacy for a variety of antidepressant strategies,   CO-MED 
was a large study funded by the National Institutes Of 
Health testing whether starting several antidepressants 
(with synergistic pharmacological effects) at the same time 
would be associated with increased efficacy. Six hundred 
and sixty-five patients with major depressive disorder were 
randomized to a 12-week treatment with escitalopram plus 
placebo, escitalopram plus buproprion sustained-release, or 
venlafaxine extended-release plus mirtazapine. Participants 
who experienced substantial benefit in the acute phase were Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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enrolled in an additional 16-week continuation treatment. 
There was no significant difference between the response 
or remission rates observed in the three study arms in either 
the acute phase (first 12 weeks) or the continuation phase 
(weeks 12–28). However, the side effect burden was signifi-
cantly higher in the two polypharmacy arms (escitalopram 
plus sustained-release buproprion: 10% maximum side effect 
burden at 12 weeks and 10% at 28 weeks, or venlafaxine 
Figure 1 Tips to help make washout easier. 
• Depending on the reason for washout, allowing the patient to have input into the decision of 
taper speed helps confirm a sense of teamwork, avoiding anger if they experience
symptoms. Whereas the more typical taper speed for selective serotonin reuptake inhibitors, 
for example, may be to halve the dose every 2 weeks, it has been our experience that when
given this choice, patients almost uniformly choose a more rapid, yet still appropriate, taper
in order to reduce the durations of any potential discomfort.
• Medications with long half-lives can temporarily be switched to similar drugs in the same
class with shorter clearance (eg, escitalopram for fluoxetine or quetiapine for aripiprazole). 
• Written taper schedules for each medication can help alleviate anxiety, especially when a
patient is at home questioning their memory of your instructions. Compliance is as much an
issue when tapering medications as it is remaining on them.
• If discontinuation symptoms do develop and cause a significant problem for the patient,
allowing the use of natural products to help relieve symptoms of agitation may be
beneficial. For example, augmenting with choline, inositol, 5-hydroxytryptophan, tyrosine,
and/or whey protein isolate might ease anxiety and irritability. St John’s wort has also been
used successfully to ease washout.
• If the current schedule of medication withdrawal is causing too much discomfort, the
patient should be instructed to return immediately to the previous dose until they can be
seen again.
• Before attempting to washout a patient with significant psychiatric symptoms, gathering 
those people who serve as their support system to gain consensus is not only important for 
the patient’s preparation, but also for their safety. The members of the support environment 
must agree to watch the patient for suicidal ideations or attempts, mood swings, or any
other potentially life-threatening worsening of symptoms. In the rare event it is needed,
they must also be prepared not to leave the patient alone. If there is not an adequate support 
system in place, the discontinuation should be delayed or abandoned.
The following principles were found to be helpful by the authors in minimizing risks with patients
when tapering medications, while realizing variations occur and individualization of washout is
important: 
• Preparation and proper informed consent gains the patient’s confidence and support.
Initially it consists of the patient borrowing from the expertise of the provider
recommending the washout. Proper management of expectations can make the difference 
between a successful taper and a potential crisis. 
• Asking patients if they have ever missed any doses of their medicine and, if so, what
symptoms they experienced, will help to identify potential risks of a more aggressive taper. 
• Part of the preparation includes the patient understanding that there may be discomfort over
the next few weeks. In fact, anticipating discontinuation symptoms from selective serotonin
reuptake inhibitors of dizziness, dry mouth, insomnia, nausea, nervousness, sweating,
anorexia, diarrhea, somnolence, and sensory disturbances (shock-like electrical sensations
or “zaps”) educates the patient as to realistic expectations.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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extended-release plus mirtazapine: 15.2% at 12 weeks and 
15.7% at 28 weeks) compared with the escitalopram-only 
arm (4.2% at 12 weeks and 5.2% at 28 weeks). This large, 
well designed, adequately powered study suggests that for 
a significant number of patients with major depression, 
polypharmacy adds to the side effect burden without an 
increase in efficacy.
A worrisome trend in modern psychopharmacology is 
the addition of atypical antipsychotics into the polyphar-
macy mix. Between 1997 and 2000, 30% of antipsychot-
ics were prescribed by nonpsychiatric physicians,26 and 
in 2005, the most common indications for antipsychotics 
were depression and bipolar disorders (39.0%), followed by 
schizophrenia/other psychotic disorders (34.5%), delirium/
dementia (7.4%), attention-deficit/conduct-disruptive 
behavior disorders (5.7%), anxiety disorders (5.5%), and 
autism (2.3%).27 A study in military veterans being treated 
for post-traumatic stress disorder found that antipsychotic 
medications were no better than placebo.28 Recent trends 
reflect increased prescribing of atypical antipsychotics 
for treatment-resistant depression and bipolar disorder, 
which are indications approved by the US Food and Drug 
  Administration, but also for treating irritability in autism, 
which is not. A search of ClinicalTrials.gov29 found hundreds 
of additional trials underway for a wide variety of new atypi-
cal antipsychotic indications, including trials of quetiapine 
for irritable bowel syndrome, fibromyalgia, insomnia, and 
benzodiazepine replacement, as well as a host of additional 
nonpsychotic psychiatric disorders.30 Despite the proven 
efficacy of antipsychotic treatments in treatment-resistant 
depression and bipolar disorder, the question remains as to 
whether modest increases in efficacy justify the side effects 
and risks associated with this class of medications, which 
include severe metabolic abnormalities and increased car-
diovascular risk.
A meta-analysis of 16 studies evaluating atypical 
antipsychotics as augmentation agents for treatment-resistant 
depression raises concerns about their increased usage.31 
Likewise, it is well known that the use of polypharmacy in 
the elderly leads to more significant risk factors, including 
morbidity and mortality.32–35 As early as 1992, it was reported 
that psychotropic agents are the most commonly misused 
drugs in the elderly and are associated with increased illness 
severity, hospitalizations, number of physician visits, and 
number of pharmacies used.36
Outside of mood disorders, the risks of polypharmacy are 
well documented. A review of antipsychotic polypharmacy 
studies compared symptoms, functioning, and/or side effects 
in 30 studies from 1966 to 2007 in which antipsychotics 
were used as monotherapy or with other antipsychotics.37 
The studies were stratified into those that recruited subjects 
who were clearly treatment-resistant to monotherapy and 
those studies where the subjects were not. In those studies 
where monotherapy had clearly failed, subjects demon-
strated greater symptom control with fewer side effects 
when additional antipsychotics were added. Those studies 
where treatment resistance was not established revealed 
mostly negative results for symptomatology/functioning 
and increases in adverse events. One of the studies reported 
that when comparing polytherapy and monotherapy, the 
median final antipsychotic dose was 78% higher, the median 
hospital stay was 55% longer, and the risk of adverse events 
was 56% higher with polytherapy.38 However, this was an 
open study. Two of the other studies were long-term (10 and 
17 years) studies of subjects who had no established treat-
ment resistance to monotherapy.39,40 These studies revealed 
an increased relative risk of death (2.5 and 2.46) in patients 
on multiple antipsychotics. This review of 30 studies con-
cluded that antipsychotic polypharmacy was supported 
only if subjects were treatment-resistant to monotherapy.37 
It should be noted that these last two studies do not account 
for illness severity.
Kingsbury41 makes the point that medications are often 
prescribed to treat a side effect of another agent. He refers 
to this as “bad polypharmacy”, and notes that it can be seen 
when clinicians are afraid of changing the status quo by 
altering a medication that may be only partially   effective. 
Often an additional medication is added to the existing 
cocktail in the hope of achieving a better therapeutic 
response, even though monotherapy might be sufficient. 
As the famous marketing pioneer, John Wanamaker, once 
proclaimed, “I know that half of my marketing dollars 
are wasted, I just don’t know which half.”42 This is not 
unlike psychiatrists evaluating a new patient presenting 
on numerous medications but not knowing which ones are 
unnecessary.
Another risk from polypharmacy is the increased adverse 
impact on patient health status. A recent study of 659 
depressed patients found that their rate of cardiovascular 
problems increased from 8.8% to 30.7% after only six 
weeks of polypharmacy.43 The life-threatening potential 
of polypharmacy is such that between 2006 and 2009, 
101 soldiers reportedly died accidentally while taking a toxic 
combination of psychotropic drugs,44 and other soldiers in 
different military branches may have been similarly affected 
but unpublished.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Rational polypharmacy
There are clearly times when polypharmacy is necessary, 
particularly when there are comorbidities requiring more 
than one class of medication or when monotherapy provides 
insufficient improvement. However, the dilemma for the 
psychiatrist is how to know if polypharmacy is needed, and 
if so, which of the overwhelming number of possible drug 
combinations are right for a particular patient. Research 
will never test all these options. Thus the psychiatrist is left 
with the perplexing decision of whether polypharmacy is 
warranted, along with which choice of medications should 
be used. The need to treat different functions of the brain or 
comorbid conditions may benefit a patient, but the current 
practice of trial-and-error prescribing is risky, especially 
when using more than one drug.
A number of authors have suggested guidelines for ratio-
nal polypharmacy. Kingsbury2 starts by defining irrational 
polypharmacy, with obvious examples such as using several 
benzodiazepines or several antipsychotics at the same time. 
He also describes how irrational polypharmacy can occur 
in practice due to lack of knowing which is the offending 
drug, fear of changing one of the drugs, laziness, not want-
ing to rock the boat, misdiagnosis, and misunderstanding of 
  pharmacology. Rational polypharmacy should be supported 
by validated double-blind, randomized controlled trials, but if 
they are lacking, it may be necessary to use mini-experiments 
within a clinic drawing on good pharmacologic decisions for 
drug selection, then collecting data and evaluating results on 
individual patients. Kingsbury goes on to suggest principles 
for rational polypharmacy, including review of clinical trials, 
overuse of benzodiazepines, a good working knowledge of 
pharmacology, and an awareness of potential pharmacody-
namic and/or pharmacokinetic drug interactions.
Preskorn and Lacey45 recognized the difficulties in finding 
randomized controlled trials on polypharmacy, mostly due 
to the fact that these studies are expensive, usually done by 
pharmaceutical developers, and are limited to only those few 
coadministered drugs that do not have potential pharmacokinetic 
interactions. Rarely would a pharmaceutical company design a 
randomized controlled trial to study each possible drug combi-
nation that might be encountered in practice. Using the success 
in the Parkinson disease model, Preskorn suggests criteria for 
rational psychotropic polypharmacy, such as having a rational 
pharmacological basis, using evidence (if any) of effectiveness, 
maintaining safety (no worse than monotherapy), no drug 
interactions, using drugs with single and specific (not broad) 
mechanisms of action, an intermediate half-life for each drug, 
and linear pharmacokinetics.
Role of washout
Even after a detailed history and diagnostic workup, the psy-
chiatrist is often faced with a key question when evaluating a 
treatment-resistant patient on polypharmacy for the first time, 
ie, how to distinguish medication effects and their adverse 
reactions from psychiatric symptoms. An overlooked tool in 
the psychiatric armamentarium to help answer this question 
is washing out a patient’s medications, thereby allowing a 
re-examination of their baseline functioning.
Making certain that the patient even needs medication 
after years of prolonged use is good clinical care. Often the 
value of washout becomes clear in patients treated as children 
or adolescents before their brains have matured, while using 
street drugs, or in the midst of a hormonal storm. Yet many 
of these patients are never taken off their medications to see 
if they are still necessary once psychological and neurophysi-
ologic maturity is completed.
For many psychiatrists, washout may seem like a barrier, 
if not a daunting experience. However, the reality of washout 
rarely lives up to these fears, and more importantly, washout 
is often clinically necessary as part of a thorough treatment 
regimen, especially in treatment-resistant patients whom the 
psychiatrist has not previously treated.
One study presented the findings from 2009 treatment-
resistant patients from seven outpatient clinics who under-
went a total medication washout as part of their psychiatric 
workup.46 Of these 2009 patients, only five patients (0.25%) 
discontinued the washout process due to either rebounding 
of their original mood disorder or discontinuation symptoms, 
while an additional 15 (0.75%) complained of an adverse 
response but continued through to the end of the washout. 
Most of the adverse events were related to mild or moder-
ate discontinuation symptoms, with no mortality or serious 
morbidity in functioning. This low rate of washout failure is 
similar to that found in a study that involved total medication 
washout of treatment-resistant patients prior to randomiza-
tion in 12 academic and outpatient psychiatric sites.47 In this 
study, only 21 of 351 patients (5.9%) could not be randomized 
due to washout failure, and, as in the previous report, there 
was neither mortality nor significant morbidity for patients 
undergoing medication washout. Furthermore, another study 
found that only four of 51 highly symptomatic patients (7.8%) 
could not tolerate washout of their antidepressant and/or mood 
stabilizing medications over a two-week period, while three 
patients experienced complete remission of their symptoms.48 
This study reported that the other patients remained stable or 
improved on clinical measures, without worsening of symp-
toms during the two weeks of psychotropic washout.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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In terms of discontinuation due to intolerance, washout 
compares very favorably with polypharmacy in treatment-
resistant patients (see Table 1). In steps 2–4 of the STAR*D 
study, the discontinuation rate due to intolerance of drug 
augmentation ranged from 19.5% to 34.1%,49 and in the 
meta-analysis of 16 atypical antipsychotic augmentation 
studies (mentioned earlier) it averaged 9.1%.31 Therefore, 
based on these studies,31,49 the dropout rates due to adding 
medications to an existing regimen range from 9.1% to 
34.1%, ie, considerably larger than the dropout rates due to 
washing out medications.47,48 These comparisons highlight 
the relative risk of adverse events between polypharmacy 
and washout. While the time of recording side effects is 
different in washout studies (1–2 weeks) and augmentation 
studies (6–12 weeks), the essential point of comparison 
at the moment is when the decision to washout or add 
more medications to the therapeutic regimen is made. It 
is at that point that risk of washout is often unrealistically 
feared.
In many instances medication stacking (or adding medi-
cations when patients complain of additional symptoms that 
may be environmentally related or due to minor cycling, 
which time alone might rebalance, resulting in the use of 
unnecessary drugs), interactions and side effects can be a 
cause of psychiatric symptoms and, in fact, these symptoms 
may improve after washout to the point where no medica-
tion may be immediately necessary.50 In one paper, washout 
was reported as aiding in the diagnosis of an extremely 
complex case, further validating its importance in difficult 
patients.51 In this case, the patient’s diagnosis was in ques-
tion for many years, and clinicians could not determine if 
he had an antisocial personality disorder or schizophrenia. 
Neuroleptics were masking true paranoia and, as the author 
noted, florid delusional behaviors became apparent in the 
drug washout period. Although seldom used, washout 
should be an essential tool for psychiatrists to consider in 
their workup of treatment-resistant patients. Table 2 com-
pares washout and polypharmacy in terms of their risks and 
benefits when using either approach with treatment-resistant 
patients. Figure 1 provides some clinically useful tips on 
how to minimize the difficulties patients may have with 
tapering medications.
Washout is not for everyone
While the above discussion focuses on the advantages of 
washout, tapering a patient off their current medications is 
not recommended for everyone. Clearly there are risks to 
washing out medications in a patient, including return or 
rebound of their medical/psychiatric problems, discontinu-
ation symptoms, withdrawal (particularly with benzodiaz-
epines), relapse, and fear of not feeling protected by whatever 
benefit the drugs may offer, to name a few. Even patients who 
presume their medication is not working may feel worse when 
their therapeutic agent is removed. Withdrawing from specific 
medications (like neuroleptics), as well as severity of illness, 
speed of withdrawal, and inpatient versus outpatient status, 
are all variables to be considered before washout.52 Patients 
with schizophrenia or bipolar disorder deserve special con-
sideration because they may appear to be healthier on their 
medication, but may develop manic or psychotic symptoms 
if taken off their current regime. While it may be helpful to 
confirm their need for medication, a careful history from 
previous treatment providers is prudent. Clinical judgment 
must not be abandoned when making this decision, and 
careful tapering, including speed of washout and severity of 
illness, is essential.
Discussion
When faced with a decision about the next treatment to 
initiate in a complex or treatment-resistant patient, the 
typical next step is to augment or switch a medication. 
A medications washout can be a helpful and valuable 
treatment. However, when assessing the risks, it is hard to 
see the addition of another medication as anything but a 
lose-lose decision. If the new medicine works, the previous 
medications are still on board, adding to the risk of side 
effects, drug interactions, and medication stacking. If the 
new medication does not work, the practitioner is back to 
the initial problem, ie, prolonging suffering and exposing 
the patient to the risks of two new drugs (the one that did 
not work and the one about to be added). In addition, there 
is a risk related to delayed improvement. Washout, on the 
other hand, offers the opportunity for clarity, ultimately 
using fewer drugs by knowing which ones are necessary, 
decreasing the risk of drug interactions, and establishing a 
true baseline for the patient. It is possible that, as a result 
of washout, the clinician will still suggest a regimen of 
multiple medications (ie, polypharmacy) as the best next 
course of action. However, washout provides the oppor-
tunity to avoid use of unnecessary medications with their 
associated risks.
Table 1 comparative estimates of complications of washout versus 
polypharmacy
Treatment modality Estimates of intolerance
Washout 5.9%–7.8%
Polypharmacy 9.1%–34.1%Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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We want to emphasize that in our arguments we concep-
tualize washout as a relatively brief, time-limited period off 
medications which would allow more precise diagnostic and 
treatment interventions. We do not advocate interruption of 
effective treatments. For most psychiatric disorders, treat-
ment nonadherence (ie, interruption of potentially useful 
treatment) is a major cause of poor treatment outcomes. 
For example, in schizophrenia, nonadherence with pre-
scribed antipsychotics is associated with poor functional 
outcomes,53 higher risk of relapse and hospitalization,54 
and increased risk of suicide.55 In our opinion, washout 
followed by improved assessment and treatment is actually 
a factor increasing adherence with long-term treatment by 
minimizing the burden of unnecessary medications and their 
associated side effects.
Conclusion
Washout may be an effective tool for physicians when the 
potential risks of adding further medications to a regimen 
outweigh the potential benefits. Re-examining the medica-
tion washout and polypharmacy challenge, the following 
inferences seem reasonable:
•	 Unwarranted fears, resistance, time constraints, or satis-
faction with the “status quo” are natural hesitations that 
may not always be in the patient’s best interests
•	 The most significant decision point is when a physician is 
trying to decide whether to washout or add more medica-
tions to the psychotropic regimen
•	 A potential risk of liability might exist if a physician does 
not demonstrate that all options (such as washout) were 
considered. “If a simple test is available that can confirm 
what is really wrong with a seriously ill patient, a doctor 
should not skip the test just because he’s fairly sure he 
already knows what is wrong”.56 It is incumbent upon 
a prescriber to consider all available information while 
concomitantly assessing risk
•	 Washing out medications in patients can be good clinical 
care and is done too infrequently
•	 A careful taper off medication with appropriate monitor-
ing has a low degree of risk for patients being able to go 
off their drugs medically
•	 Polypharmacy can be harmful, due to side effects, drug-
drug interactions, costs, and potential unnecessary stack-
ing of medications
•	 When polypharmacy is appropriate, there is a paucity of 
literature regarding which medication options to use in 
which patient.
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